natasaadzic / iStockphoto.com
4 September 2018Big Pharma
EMA cuts MHRA out of drug reviews ahead of Brexit
The European Medicines Agency (EMA) has reportedly put a stop to the UK’s role in evaluating new EU medicines for sale as Brexit looms.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
24 August 2018 The UK will fall outside of the European Medicines Agency in the event of a no-deal Brexit, leaving the Medicines and Healthcare Products Regulatory Agency to take on the functions currently undertaken by the EU for medicines on the UK market.
Big Pharma
4 October 2018 The UK’s Medicines and Healthcare Products Regulatory Agency is seeking industry views on a no-deal Brexit scenario.
Big Pharma
12 November 2018 Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.
Editor's picks
Editor's picks
Big Pharma
24 August 2018 The UK will fall outside of the European Medicines Agency in the event of a no-deal Brexit, leaving the Medicines and Healthcare Products Regulatory Agency to take on the functions currently undertaken by the EU for medicines on the UK market.
Big Pharma
4 October 2018 The UK’s Medicines and Healthcare Products Regulatory Agency is seeking industry views on a no-deal Brexit scenario.
Big Pharma
12 November 2018 Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.
Big Pharma
24 August 2018 The UK will fall outside of the European Medicines Agency in the event of a no-deal Brexit, leaving the Medicines and Healthcare Products Regulatory Agency to take on the functions currently undertaken by the EU for medicines on the UK market.
Big Pharma
4 October 2018 The UK’s Medicines and Healthcare Products Regulatory Agency is seeking industry views on a no-deal Brexit scenario.
Big Pharma
12 November 2018 Associations representing the pharmaceutical and biotechnology fields have said that the UK should maintain “close cooperation” with the EU post-Brexit, to ensure that access to safe and effective medicines continues in both markets.